Featured Press Releases

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

  • 02 Oct 2024

LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a...

Improved Pharma Brings Onboard Micro-DSC Hot-Stage System

Improved Pharma Brings Onboard Micro-DSC Hot-Stage System

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Appoints Michael Rossi to Board

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

  • SQ Innovation
  • 29 Apr 2026
Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

  • Rapid Nexus
  • 29 Apr 2026
Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

  • Mundipharma
  • 28 Apr 2026
Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

  • Cellenkos, Inc.
  • 27 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.